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The Impact of Pancreatic Beta Cell Heterogeneity on Type 1 Diabetes
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Abstract
Purpose of Review To discuss advances in our understanding of beta-cell heterogeneity and the ramifications of this for type 1
diabetes (T1D) and its therapy.
Recent Findings A number of studies have challenged the long-standing dogma that the majority of beta cells are eliminated in
T1D. As many as 80% are present in some T1D subjects. Why don’t these cells function properly to release insulin in response to
high glucose? Other findings deploying single-cell “omics” to study both healthy and diseased cells—from patients with both
T1D and type 2 diabetes (T2D)—have revealed cell subpopulations and heterogeneity at the transcriptomic/protein level between
individual cells. Finally, our own and others’ findings have demonstrated the importance of functional beta-cell subpopulations
for insulin secretion.
Summary Heterogeneity may endow beta cells with molecular features that predispose them to failure/death during T1D.
Keywords Beta cell . Type 1 diabetes . Insulin . Heterogeneity . Transcriptomics . Imaging
Introduction
The incidence rate of type 1 diabetes (T1D) is ~20 per 100,000
individuals under 15 years in the USA and UK, with 13,000
new cases diagnosed each year [1]. Classically, T1D has been
thought to involve the progressive, and ultimately near-
complete (> 90%), destruction of beta cells within the pancre-
atic islet [2]. The selective loss of beta cells results from im-
mune attackmediated by CD4+ and CD8+ Tcells recruited by
islet-derived auto-antigens [3, 4], notably insulin, GAD65,
IA-2, ZnT8 [5], Chromogranin A (ChgA) [6], and IGRP
(G6PC2) [7], as well as hybrid peptides formed between
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insulin and ChgA or IAPP [8]. Correspondingly, islet auto-
antigen load is predictive of seroconversion to T1D [9].
Auto-antigens are presented at the beta-cell surface by class
I human leukocyte antigen (HLA; also called major histocom-
patibility complexes, MHC) and are presented by antigen pre-
senting cells by class II HLA molecules. Emphasizing the
importance of antigen presentation in disease etiology, the
genetic variants most strongly associated with T1D risk are
HLA class II genes, with HLA class I genes also contributing.
In addition, genetic variants associated with T1D risk include
those encoding T cell activity and antigen recognition (e.g.,
PTPN2 [10], CTLA4 [11]), and cytokine signaling (e.g., IL2,
IL2RA, IL10). Nonetheless, the extent to which this reflects
failures in the immune system versus alterations at the level of
the beta cell is not fully resolved. For example, PTPN2 plays
an important role in beta-cell responses to inflammatory cyto-
kines, including apoptosis [10].
Although the classical conception of T1D involves the es-
sentially complete loss of beta cells in T1D, more recent stud-
ies [12–14] have demonstrated that a significant proportion of
T1D patients retain detectable levels of circulating C-peptide,
indicating at least partially preserved insulin secretion and
(partly) functional beta cells. Correspondingly, at the histolog-
ical level, patients diagnosed with T1D at < 7 years of age
display a “classical” picture of > 90% loss of insulin-
containing islets, whereas those diagnosed later (> 13 years)
retain a substantial fraction (20–80%) [15]. It is possible that
less-functional cells among a heterogeneous population selec-
tively survive, as has been suggested by functional heteroge-
neity among beta cells in T2D [16, 17]. At present, however,
the mechanisms through which the extant beta-cell population
is rendered sub-functional in T1D have remained obscure.
Consideration of how healthy pancreatic beta cells respond
to acute challenge with elevated glucose concentrations is rel-
evant here. High glucose levels prompt accelerated uptake and
metabolism of the sugar, chiefly controlled by flux through the
low-affinity glucose-phosphorylating enzyme glucokinase
(hexokinase IV) [18]. Enhanced generation of ATP by mito-
chondria [19], and the closure of ATP-sensitive K+ channels
(KATP) [20], then leads to Ca
2+ influx through voltage-gated
Ca2+ channels [21]. Other pathways, including mitochondrial
GTP synthesis [22], as well as the mitochondrial export of
metabolites including citrate [23], isocitrate [24] or glutamate
[25], may further potentiate the effects of increased Ca2+.
Importantly, glucose-stimulated insulin secretion is pulsatile,
and likely to be driven by low- (5–15 min) and high- (1–
5 min) frequency oscillations in intracellular free Ca2+ [26].
Studies in humans [27] reveal relatively modest effects on
serum fasting glucose and glucose tolerance from the surgical
removal of 50% of the pancreas, while in non-human primates
[28], hemi-pancreatectomy had more marked effects. These
findings make it unlikely that frank diabetes in patients with
> 50% of their beta cells remaining can be attributed to beta-
cell loss alone (note, however, that there are wide inter-
individual differences in beta-cell mass between non-diabetic
individuals [29] making the definition of “normal” beta-cell
mass challenging).
Why are the remaining beta cells from these patients
unable to produce sufficient hormone to control blood
glucose levels? Whereas defects in the mitochondrial oxi-
dative metabolism have been described in islets from type
2 diabetes (T2D) patients [30], and likely contribute to
impaired insulin secretion in that disease, their role, if
any, in T1D islets is uncertain. Of note, the existing ge-
netic data argue for distinct etiologies for T1D and T2D,
with relatively little overlap between the genome-wide as-
sociation loci identified in studies for T2D [31] and T1D
[32]. Indeed, only a single locus (GLIS3), of the hundreds
identified for each disease, overlaps in T1D and T2D.
However, recent studies [33] have increased the number
of T2D loci (~420). The study of these may reveal greater
overlap with the 60 variants associated with T1D, and
thus, potentially, some shared disease mechanisms.
Islet function is impaired prior to the onset of diabetes in
animal models of T1D [34, 35]. In human, in vivo measure-
ments show signs of beta-cell dysfunction up to 5 years prior
to diabetes onset [36•]. These findings suggest that beta cells
become defective before they are killed outright.
Correspondingly, insults that pertain to T1D, e.g., the release
from inflammatory cells of sub-lethal cytotoxic cytokines
such as interferon γ (IFNγ), interleukin-1β (IL-1β), and tu-
mor necrosis factor-α (TNF-α), impair beta cell metabolism
and the usual increases in cytosolic ATP/ADP ratio following
nutrient stimulation. These effects are observed both in vivo in
non-obese diabetic (NOD) mice [37], and in vitro [38] in
isolated islets, and are thus likely to compromise glucose-
stimulated insulin secretion.
In this report, we discuss the notion that beta cell heteroge-
neity and the existence of functional beta cell subpopulations
[39, 40] may be relevant to the normal control of insulin se-
cretion and may become defective in the context of T1D.
Furthermore, we raise the possibility that the preservation of
heterogeneity may provide a new preventative or therapeutic
strategy in some settings.
Single Cell and Subpopulation Analyses
of Beta Cell Heterogeneity
Although the concept of functional and phenotypic beta cell
heterogeneity is not new, advances in single-cell analysis have
contributed to an explosion of information on this topic in the
last 3 years. Nearly all of these examined either mouse cells or
human cells from healthy or T2D donor islets, in part due to
the limited availability of T1D islets. Nevertheless, “baseline”
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heterogeneity and a pathological heterogeneity should have
implications for type 1 diabetes as well.
The Kubicek lab first reported the application of single-cell
transcriptomics to human islet cells. In Li et al. [41], they
reported the comparison of 64 human pancreatic cells isolated
by fluorescence-activated cell sorting (FACS) and processed
by Smart-Seq2 for high-throughput sequencing. Although on-
ly 12 beta cells were identified, these showed transcriptome
heterogeneity for genes such as DLK1 (which has been asso-
ciated with T1D by GWAS [42]). In another first, the Kaestner
lab used CyTOF single-cell mass cytometric analysis to inter-
rogate the levels of 24 different proteins on millions of human
islet cells [43]. Heterogeneous levels of several markers were
observed in beta cells, including CD9 (see below) and the
proliferation marker Ki67, revealing four subpopulations after
viSNE analysis (a variant of Stochastic Neighbour
Embedding, t-SNE, used to present single-cell data in two
dimensions [44]).
Several groups have now performed large-scale single-cell
transcriptome analyses of human beta cells [16, 45–49], mouse
beta cells [50, 51], or both [52]; those which focus on the
changes associated with T2D will be discussed later. Work
performed in the laboratory of van Oudenaarden identified
three beta cell subpopulations by RaceID clustering and found
that some of the strongest genes distinguishing these clusters
were involved in ER/oxidative stress [46]. Baron et al. [52] also
reported stress marker-related heterogeneity in normal human
beta cells, but their principal component analysis resolved two
populations. Differential expression of UCN3, a marker of beta
cell maturity [53], was also observed. A recent publication from
the Gromada group supports the idea that human beta-cell sub-
populations are distinguished by different ER stress states and
describes differential expression of some of the same genes
[49]. In addition, this report links ER stress with proliferative
capacity and a reduction of beta cell function including insulin
production. Chronic ER stress was also shown to correlate with
heterogeneous expression of aging markers including Igf1r
[54]. Enge et al. [48], in contrast, report age-related increases
in transcriptional “noise”within the beta cell transcriptome, but
cell subtypes were not detected.
Zeng et al. [50] and Qiu et al. [51] performed single-cell
transcriptome analyses of mouse beta cells. In the Zang study,
transcriptional heterogeneity at observed and projected time
points was compared by arranging trajectories based on tran-
scriptome similarity (“pseudotimelines”). The authors con-
clude that heterogeneity is persistent and that, consistent with
the report above, ROS-induced ER stress promotes prolifera-
tion of the associated cell subset [50]. Qiu et al. report a low
degree of transcriptome heterogeneity in mature mouse beta
cells, but point out that post-transcriptionally specified hetero-
geneity would not be detected in these studies [51].
Although these studies do not directly assay or model T1D,
elements of the observed heterogeneity are potentially quite
relevant. The inflammatory environment to which a beta cell
is exposed during insulitis is known to promote proliferation
[55], and it seems plausible that subpopulations of normal beta
cells that demonstrate proliferative capacity would be those
most likely to respond in T1D. In addition, reports of ER
stress-related heterogeneity seem relevant to the T1D environ-
ment, where ER stress is strongly induced [56]. These single-
cell studies may reveal changes in heterogeneity reflecting
differential survival of subtypes and/or adaptations to the pro-
gressive immune assault on the beta cell pool (Fig. 1a). Of
note, the surviving cell population includes few if any prolif-
erating cells [58], perhaps suggesting preferential killing of
dividing cells (with some exceptions as broached later).
Intriguingly, prior to disease onset, antibody-positive subjects
were found to have unaltered beta cell mass (as assessed by
insulin positivity) but an increased proinsulin-positive area,
perhaps suggestive of (a) increased proliferation prior to im-
mune attack and (b) impaired function or cellular “identity”
[59].
Functional Heterogeneity of Healthy Beta
Cells Within the Intact Islet
Pioneering work conducted almost 30 years ago provided the
first evidence that beta cells display marked functional hetero-
geneity, including differences in ion channel conductance,
Ca2+ fluxes, metabolism, insulin expression/secretion, and
proliferation [60–63]. Such heterogeneity may also render be-
ta cells sensitive to insult: the most glucose-sensitive beta cells
are also the most susceptible to cytokine-induced stress [64],
whereas proliferation is lowest in cells with the highest levels
of pro-inflammatory NF-κB signaling [65]. Heterogeneity is
further shaped by the islet context, where beta cells are elec-
trically coupled via gap junctions, and are also subjected to
modulatory inputs from neighboring cells (e.g., α cells, δ
cells) [66–70], together ensuring the coordinated regulation
of insulin secretion. The complex signaling interactions
afforded by the islet architecture give rise to “functionally
competent” metabolically adapted subpopulations that are
able to exert disproportionate influence over islet function
[39, 40]. Whether this leads to greater robustness of the islet,
or actually increases susceptibility, is unclear. Similarly, tran-
scriptionally immature subpopulations have been discovered
in the adult islet that display reduced glucose uptake, mito-
chondrial function, and Ca2+ fluxes, but enhanced prolifera-
tive capacity [71, 72]. These studies suggest an association
between proliferation state and immaturity: indeed c-myc
overexpression to force replication induces a neonatal-like
beta cell state [73]. Notably, single-cell sequencing ap-
proaches applied to dissociated cells are unlikely to fully re-
capitulate the heterogeneity imparted by interactions at the
level of the islet, especially as transcriptional changes can
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occur rapidly following isolation and sensitivity of even
RNASeq is still relatively limited. Moreover, some of the
“functionally competent” subpopulations identified so far are
more sensitive to stress, possibly due to lowered Pdx1 levels
or glucokinase activity [74, 75], and may occupy an apoptotic
or necrotic fraction that is discarded following dissociation
[39]. Other possibilities include the dependence of functional
subpopulations on islet architecture for their phenotype, or
changes in stability (original studies only tracked fate over a
few hours [39]). Key questions therefore include whether the
stresses associated with T1D drive beta cells towards more or
less proliferation, or affect differentiation state and identity: it
would be of interest to determine in T1D islets the proportion
of the four beta-cell subtypes as described recently [77]. The
fact that cryopreserved pancreata comprise the bulk of sam-
ples from individuals with T1D reinforces the need to deploy
approaches that can interrogate beta cells directly in situ in the
tissue context with high precision (e.g., laser microdissection
followed by RNASeq; STARmap, CLARITY, imaging mass
cytometry/multiplexed ion beam imaging, or other highly
multiplexed imaging approaches) [78–81].
Implying functional relevance for connections between
functionally heterogeneous beta cells, we [66, 70] and others
[67] have shown the critical importance of gap junctions,
c
Cx36
Cx36
Glucagon Glucagon
Insulin Insulin
Normal T1D
Somatostatin Somatostatin
= α cell = δ cell = β cell = Functional subpopulation = +ve = -ve
Normal AA+ T1Da
= β cell = Immature subpopulation = Stressed subpopulation = Failed β cell
Normal AA+ T1D
Proliferation
Survival
T1D antigens
Identity
Stemness
Insulin
= Mature β cell = Resistant β cell = Immune infiltration
b
= Insulin
Fig. 1 Working interpretation of
the role of beta cell heterogeneity
in T1D. a Beta cells possess
molecular heterogeneity giving
rise to subpopulations, some of
which are functionally competent.
Shifts in the proportions of these
subpopulations, in particular
those with proliferative or ER-
stressed phenotypes, may be
expected to occur during T1D
progression. b Beta cell
subpopulations that are resistant
to immune attack occur in NOD
mice, with lowered insulin
release, lowered expression of
genes for function and
metabolism, increased expression
of genes for T1D antigens (AA;
auto-antigen), but increased
markers of proliferation,
stemness, and survival. The table
shows characteristics of immune
attack-resistant cells characterized
in [76]. c The islet hosts electrical
(gap junction; Cx36) and
paracrine loops, which give rise to
functional beta-cell
subpopulations. Failure in
intercellular communication has
been shown to occur in response
to pro-inflammatory conditions
[39, 83]. Figures were adapted
from Servier Medical Art under a
CC-BY3.0 license (https://
creativecommons.org/licenses/
by/3.0/)
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formed by connexin36 (Gjd2), for the normal control of insu-
lin secretion. Importantly, we have shown that aging [82] or
conditions mimicking the diabetic milieu, including those rel-
evant to T1D such as elevated cytokine levels [66, 83], impair
beta cell to beta cell communication. This is also altered—as
measured in isolated islets—as a function of body mass index,
consistent with a role for lowered intercellular communication
in the metabolic syndrome and prediabetes [66]. Analogous
studies are lacking in islets obtained from T1D subjects.
Changes in Beta Cell Identity
and Heterogeneity in T1D and T2D
Several recent reports have emphasized the likely importance
of changes in beta-cell identity in T2D at the population (i.e.,
whole islet) level [84, 85]. The extent to which this may reflect
changes in the expression of genes within distinct beta-cell
subpopulations, or altered ratios of these subpopulations, in
disease is unknown.
A report byWang et al. [17] was the first to describe single-
cell transcriptome analysis of human beta cells from a T1D
islet. Unfortunately, the difficulty of obtaining and processing
such islets and the scarcity of beta cells within them meant
only six cells were analyzed and no conclusions could be
reached regarding heterogeneity. However, by comparing beta
cells from T2D and healthy donors, they observed many cells
that appeared to have de-differentiated, adopting a tran-
scriptome resembling juvenile beta cells. The Sandberg labo-
ratory also compared normal and T2D beta cells, and identi-
fied five subpopulations [16]. Among the differentially
expressed genes was RBP4, which has been reported to be
downregulated in T1D patients [86]. Xin et al. [45] and
Lawlor et al. [47] did not detect beta cell subpopulations in
their respective T2D vs. healthy islet cell-type comparisons,
but the latter reported expression of T1D-associated MEG3
[42] in human beta cells. A renewed interest in the application
of single-cell analysis to surviving beta cells in T1D islets
should help to determine whether changes in heterogeneity
are associated with this disease as well.
How might heterogeneity in the islet contribute to T1D?
Pro-inflammatory cytokines associated with islet dysfunction
during T1D are known to perturb many facets of beta cell
function including metabolic and electrical activity, insulin
granule synthesis/content, and gap junction coupling [39, 83,
87]. This could feasibly alter vulnerability to insult as well as
shift the balance between the different functional subpopula-
tions. Thus, subpopulations of immature proliferative beta
cells with reduced functional capacity are relatively resistant
to cell death [71, 76••]. On the other hand, increased beta cell
metabolic or electrical activity can increase susceptibility to
cell death [88, 89].
In particular, a population of beta cells has been shown to
develop during the onset of T1D in NOD mice. These cells
have characteristics of immaturity, including reduced insulin
granule content and increased expression of genes for prolif-
eration, immune inhibition, and “stemness” [76••]. “Deep
phenotyping” of the resistant population showed changes in
beta cell identity redolent of those observed in human type 2
diabetes [18] and included the upregulation of beta-cell
“disallowed” genes [90], such as Acot7 [91] (Fig. 1b). These
findings again point to similar dysfunction in the case of sur-
viving T1D beta cells and the changes observed in T2D. The
extent to which these changes are reactive, i.e., the conse-
quence in both instances of hyperglycemia or the inflamma-
tory environment, requires further exploration. Additionally,
an interesting recent report [92] demonstrates that expression
on beta cells of co-inhibitory receptor-programmed death-
ligand 1 (PD-L1) restrains T cell reactivity in both non-
obese diabetic (NOD) mice and human T1D patients, sugges-
tive of an attempt by beta cells to escape cell killing. Whether
the induction of this gene reflects an intrinsic (i.e., cell auton-
omous) property of the responding beta cells (and thus which
sub-population?), rather than the local nature of T cell expo-
sure, represents an interesting question for the future.
Conversely, metabolically adapted and functionally
competent beta cells are more sensitive to the effects of
the cytokines IL-1β and interleukin-6 (IL-6) [39], and
would be expected to fail early in T1D due to ER stress
given their low levels of sarco(endo-)plasmic reticulum
Ca2+ ATPase-2 (SERCA2). This probably reflects the
differing proliferative and glucose uptake capacities of
the different subpopulations [64, 71, 73], as well as the
sensitivity of electrical coupling to inflammatory cyto-
kines and other insults [66, 83]. In any case, function
and proliferation need to be carefully controlled in the
normal islet and shifts to either extreme may render beta
cells susceptible to failure during T1D. Paracrine path-
ways may also become perturbed during T1D, leading to
apparent loss of heterogeneity. For example, a reduction
in beta cell function and/or number would be expected to
increase glucagon secretion due to loss of negative feed-
back. Likewise, changes in α cell or δ cell function and/
or number may dysregulate glucagon, somatostatin, and
insulin secretion due to the loss of paracrine feedback
loops between islet cell subtypes, notably those feedback
loops existing between beta cells and delta cells or be-
tween alpha cells and delta cells that serve to set the
range of insulin and glucagon secretion [68]. From this,
it should be clear that functional heterogeneity in the
islet may exert a large and dynamic influence on beta
cell function during T1D (Fig. 1c). Methods to preserve
specific subpopulations or paracrine signals are thus like-
ly to increase the resilience of islets during the early
stages of T1D.
Curr Diab Rep  (2018) 18:112 Page 5 of 9  112 
Relevance of Beta Cell Heterogeneity for T1D
Pathogenesis and Therapy
Studies of isolated islets from patients with T1D have shown
that biphasic insulin secretion can be restored in some indi-
viduals following culture in a non-diabetogenic environment
[93]. However, it is unlikely that the function of the remaining
beta cells can be rescued in vivo, as studies in patients with
allografts plus immunosuppression showed no restoration of
endogenous insulin release [12]. However, further studies are
warranted during the earlier stages of T1D when previous
immune attack and destruction may not be so extensive, or
following treatments that exert longer term and improved gly-
cemic control (e.g., closed loop pumps) [78]. Many current
immunosuppressive regimes, including the use of rapamycin
(sirolimus) [94], exert deleterious effects on beta cell function
via effects on mitochondrial respiration and as such may not
be optimal during islet transplantation. Furthermore, clinical
trials are only beginning to demonstrate rescuing beta cell
function as a therapeutic strategy (e.g., Verapamil [95•]).
Another consideration is whether beta cell subpopulations
known to be susceptible to stress—and which might therefore
be preferentially rendered inactive or destroyed in disease—can
be protected to preserve islet function for as long as possible
during infiltration. While both immune infiltration and beta cell
decline have been shown to be highly variable in T1D [96•],
functionally competent-sensitive subpopulations may neverthe-
less succumb early. This is consistent with the rapid decline in
hub cells and gap junction coupling following pro-inflammatory
cytokine exposure [39, 83]. On the other hand, the emergence of
cells resistant to cell death occurs as early as 3–4 weeks in NOD
mice when insulitis is verymild [76••]. A better understanding of
the role for such subpopulations will be key to developing a
clearer picture of their fate during T1D, as well as their cellular
and molecular signatures. Along similar lines, can immune
attack-resistant beta cell subpopulations be harnessed either early
in T1D to confer resistance, or conversely repopulated later in
T1D using, e.g., in vivo reprogramming strategies [97]? It will be
important to study whether these populations are functional on a
background of loss of other beta cell subpopulations due to
changes in paracrine and electrical inputs.
Lastly, stem cell-derived beta cells or islets are likely to be
transformative in the treatment of T1D following encapsulation
todecrease immuneattack[98].Engineeringsuchtissuetopossess
highly functional and/or immune-resistant beta cell subpopula-
tions could increase graft longevity and performance, especially
if such stem cell-derived beta cells prove to be less immunogenic.
Conclusions
It should be clear that beta cell heterogeneity is critical for
normal islet function, and shifts in this parameter may
predispose beta cells to metabolic stress. While we recognize
that most studies so far have been performed in tissue from
healthy or T2D individuals, many molecular features of the
identified beta cell subpopulations could render them more
susceptible to both immune damage (i.e., ER stress) and loss
of insulin secretory capacity (i.e., proliferation) during T1D.
Using next-generation approaches applied to isolated islets, or
more likely cryo-preserved pancreatic tissue, it will be inter-
esting to see which features of heterogeneity may be preserved
(or different) between T1D and T2D.
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